{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:57Z","timestamp":1790207757693,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04428-w","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:08:03Z","timestamp":1666984083000},"page":"4915-4923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review"],"prefix":"10.1007","volume":"149","author":[{"given":"Hardik","family":"Sheth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sewanti","family":"Limaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Shreenivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"issue":"5","key":"4428_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21(5):671\u2013684. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"key":"4428_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/jgo.2016.10.01","volume":"8","author":"DH Ahn","year":"2017","unstructured":"Ahn DH, Bekaii-Saab T (2017) Biliary cancer: intrahepatic cholangiocarcinoma vs extrahepatic cholangiocarcinoma vs gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol 8:293\u2013301","journal-title":"J Gastrointest Oncol"},{"issue":"30","key":"4428_CR3","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2217\/fon-2020-0429","volume":"16","author":"TS Bekaii-Saab","year":"2020","unstructured":"Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T et al (2020) FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 16(30):2385\u20132399. https:\/\/doi.org\/10.2217\/fon-2020-0429 (Epub 2020 Jul 17)","journal-title":"Future Oncol"},{"issue":"2","key":"4428_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jhep.2021.02.032","volume":"75","author":"G Cristinziano","year":"2021","unstructured":"Cristinziano G, Porru M, Lamberti D, Buglioni S, Rollo F, Amoreo CA et al (2021) FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. J Hepatol 75(2):351\u2013362. https:\/\/doi.org\/10.1016\/j.jhep.2021.02.032 (Epub 2021 Mar 17 PMID: 33741397)","journal-title":"J Hepatol"},{"issue":"3","key":"4428_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/annonc\/mdt419","volume":"25","author":"R Dienstmann","year":"2014","unstructured":"Dienstmann R, Rodon J, Prat A et al (2014) Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 25(3):552\u2013563. https:\/\/doi.org\/10.1093\/annonc\/mdt419","journal-title":"Ann Oncol"},{"key":"4428_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","volume":"40","author":"O Do-Youn","year":"2022","unstructured":"Do-Youn O, He AR, Qin S, Chen LT, Okusaka T, Vogel A et al (2022) A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol 40:378\u2013378. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.378","journal-title":"J Clin Oncol"},{"key":"4428_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fonc.2019.01121","volume":"9","author":"K Gondkar","year":"2019","unstructured":"Gondkar K, Patel K, Patil Okaly GV, Nair B, Pandey A, Gowda H, Kumar P (2019) Dickkopf homolog 3 (DKK3) acts as a potential tumor suppressor in gallbladder cancer. Front Oncol 9:1121. https:\/\/doi.org\/10.3389\/fonc.2019.01121","journal-title":"Front Oncol"},{"issue":"3","key":"4428_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/cells10030511","volume":"10","author":"K Gondkar","year":"2021","unstructured":"Gondkar K, Sathe G, Joshi N, Nair B, Pandey A, Kumar P (2021) Integrated proteomic and phosphoproteomics analysis of DKK3 signaling reveals activated kinase in the most aggressive gallbladder cancer. Cells 10(3):511. https:\/\/doi.org\/10.3390\/cells10030511","journal-title":"Cells"},{"issue":"3","key":"4428_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal L, Saha SK, Liu LY et al (2017) Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 7(3):252\u2013263. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1000","journal-title":"Cancer Discov"},{"issue":"8","key":"4428_CR10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"L Goyal","year":"2019","unstructured":"Goyal L, Shi L, Liu LY et al (2019) TAS-120 Overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov 9(8):1064\u20131079. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0182","journal-title":"Cancer Discov"},{"key":"4428_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102170","volume":"95","author":"L Goyal","year":"2021","unstructured":"Goyal L, Kongpetch S, Crolley VE, Bridgewater J (2021) Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev 95:102170. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102170","journal-title":"Cancer Treat Rev"},{"key":"4428_CR12","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","volume":"40","author":"L Goyal","year":"2022","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle J, Karasic T et al (2022) Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements. J Clin Oncol 40:4009\u20134009. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4009","journal-title":"J Clin Oncol"},{"issue":"20","key":"4428_CR13","doi-asserted-by":"publisher","first-page":"8180","DOI":"10.1073\/pnas.87.20.8180.PMC54916.PMID2172978","volume":"87","author":"E Houssaint","year":"1990","unstructured":"Houssaint E, Blanquet PR, Champion-Arnaud P, Gesnel MC, Torriglia A, Courtois Y, Breathnach R (1990) Related fibroblast growth factor receptor genes exist in the human genome. Proc Natl Acad Sci USA 87(20):8180\u20138184. https:\/\/doi.org\/10.1073\/pnas.87.20.8180.PMC54916.PMID2172978","journal-title":"Proc Natl Acad Sci USA"},{"key":"4428_CR14","unstructured":"Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 1975\u20132014. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2014\/. Accessed 20 December 2018"},{"issue":"2","key":"4428_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1159\/000509075.PMID:32999653;PMCID:PMC7506383","volume":"13","author":"PM Kasi","year":"2020","unstructured":"Kasi PM (2020) Favorable outcomes in FGFR fusion-positive cholangiocarcinomas and evolution on treatment noted on circulating tumor DNA liquid biopsies. Case Rep Oncol 13(2):941\u2013947. https:\/\/doi.org\/10.1159\/000509075.PMID:32999653;PMCID:PMC7506383","journal-title":"Case Rep Oncol"},{"issue":"8","key":"4428_CR16","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/jid.2009.97","volume":"129","author":"M Katoh","year":"2009","unstructured":"Katoh M (2009) FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J Invest Dermatol 129(8):1861\u20131867. https:\/\/doi.org\/10.1038\/jid.2009.97","journal-title":"J Invest Dermatol"},{"issue":"12","key":"4428_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW et al (2019) First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov 9(12):1696\u20131707. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0555 (Epub 2019 Oct 1 PMID: 31575541)","journal-title":"Cancer Discov"},{"key":"4428_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01100-3","author":"G King","year":"2021","unstructured":"King G, Javle M (2021) FGFR inhibitors: clinical activity and development in the treatment of cholangiocarcinoma. Curr Oncol Rep. https:\/\/doi.org\/10.1007\/s11912-021-01100-3","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"4428_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22(5):690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9","journal-title":"Lancet Oncol"},{"issue":"16","key":"4428_CR20","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-12-3950","volume":"73","author":"RG Liao","year":"2013","unstructured":"Liao RG, Jung J, Tchaicha J et al (2013) Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 73(16):5195\u20135205. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3950","journal-title":"Cancer Res"},{"issue":"6","key":"4428_CR21","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1021\/acs.jmedchem.8b01531","volume":"62","author":"X Lu","year":"2019","unstructured":"Lu X, Chen H, Patterson AV, Smaill JB, Ding K (2019) Fibroblast Growth Factor Receptor 4 (FGFR4) selective inhibitors as hepatocellular carcinoma therapy: advances and prospects. J Med Chem 62(6):2905\u20132915. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01531 (Epub 2018 Nov 16 PMID: 30403487)","journal-title":"J Med Chem"},{"issue":"30","key":"4428_CR22","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.2217\/fon-2020-0299","volume":"16","author":"S Makawita","year":"2020","unstructured":"Makawita S, Abou-Alfa KG, Roychowdhury S, Sadeghi S, Borbath I, Goyal L et al (2020) Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial. Future Oncol 16(30):2375\u20132384. https:\/\/doi.org\/10.2217\/fon-2020-0299 (Epub 2020 Jun 25)","journal-title":"Future Oncol"},{"issue":"3","key":"4428_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00535-020-01735-2","volume":"56","author":"Y Maruki","year":"2021","unstructured":"Maruki Y, Morizane C, Arai Y et al (2021) Molecular detection and clinicopathological characteristics of advanced\/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) [published correction appears in J Gastroenterol 2020 Dec 30]. J Gastroenterol 56(3):250\u2013260. https:\/\/doi.org\/10.1007\/s00535-020-01735-2","journal-title":"J Gastroenterol"},{"issue":"2","key":"4428_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","volume":"120","author":"V Mazzaferro","year":"2019","unstructured":"Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G et al (2019) Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 120(2):165\u2013171. https:\/\/doi.org\/10.1038\/s41416-018-0334-0 (Epub 2018 Nov 13)","journal-title":"Br J Cancer"},{"key":"4428_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2018.08.00","author":"R Mehrotra","year":"2018","unstructured":"Mehrotra R, Tulsyan S, Hussain S, Mittal B, Saluja SS, Singh S et al (2018) Genetic landscape of gallbladder cancer: global overview. Mutat Res\/rev Mutat Res. https:\/\/doi.org\/10.1016\/j.mrrev.2018.08.00","journal-title":"Mutat Res\/rev Mutat Res"},{"issue":"2","key":"4428_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT et al (2022) Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase i dose-expansion Study. Cancer Discov 12(2):402\u2013415. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0697 (Epub 2021 Sep 22 PMID: 34551969)","journal-title":"Cancer Discov"},{"key":"4428_CR27","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","volume":"37","author":"JO Park","year":"2019","unstructured":"Park JO, Feng YH, Chen YY, Wu-Chou S, Do-Youn O, Shen L et al (2019) Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol 37:4117\u20134117","journal-title":"J Clin Oncol"},{"key":"4428_CR28","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/CMAR.S164535","volume":"10","author":"Y Que","year":"2018","unstructured":"Que Y, Liang Y, Zhao J et al (2018) Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis. Cancer Manag Res 10:2141\u20132150. https:\/\/doi.org\/10.2147\/CMAR.S164535","journal-title":"Cancer Manag Res"},{"issue":"2","key":"4428_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5114\/ceh.2019.85166","volume":"5","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Thandra KC, Barsouk A (2019) Epidemiology of gallbladder cancer. Clin Exp Hepatol 5(2):93\u2013102. https:\/\/doi.org\/10.5114\/ceh.2019.85166","journal-title":"Clin Exp Hepatol"},{"issue":"22","key":"4428_CR30","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","volume":"80","author":"H Sootome","year":"2020","unstructured":"Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K et al (2020) Futibatinib Is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res 80(22):4986\u20134997. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2568 (Epub 2020 Sep 24 PMID: 32973082)","journal-title":"Cancer Res"},{"issue":"45","key":"4428_CR31","doi-asserted-by":"publisher","first-page":"E4869","DOI":"10.1073\/pnas.1403438111","volume":"111","author":"L Tan","year":"2014","unstructured":"Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M et al (2014) Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A 111(45):E4869\u2013E4877. https:\/\/doi.org\/10.1073\/pnas.1403438111 (Epub 2014 Oct 27 PMID: 25349422 PMCID: PMC4234547)","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"4428_CR32","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"issue":"12","key":"4428_CR33","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1158\/1535-7163.MCT-17-0309","volume":"16","author":"E Venetsanakos","year":"2017","unstructured":"Venetsanakos E, Brameld KA, Phan VT, Verner E, Owens TD, Xing Y et al (2017) The Irreversible covalent fibroblast growth factor receptor inhibitor PRN1371 exhibits sustained inhibition of FGFR after drug clearance. Mol Cancer Ther 16(12):2668\u20132676. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0309 (Epub 2017 Oct 4 PMID: 28978721)","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"4428_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1517\/14740338.2012.712108.PMID22861374.S2CID2178331","volume":"11","author":"A Zivi","year":"2012","unstructured":"Zivi A, Cerbone L, Recine F, Sternberg CN (2012) Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert Opin Drug Saf 11(5):851\u2013859. https:\/\/doi.org\/10.1517\/14740338.2012.712108.PMID22861374.S2CID2178331","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04428-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:12:57Z","timestamp":1689430377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04428-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4428"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04428-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"3 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the individual included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}